

**BORSON LAW GROUP, PC**  
INTELLECTUAL PROPERTY LAW  
1320 WILLOW PASS ROAD, SUITE 490  
CONCORD, CALIFORNIA 94520-5232  
TEL: (925) 395-2060  
FAX: (925) 395-2061  
WWW.BORSONLAW.COM

RECEIVED  
CENTRAL FAX CENTER  
JUL 22 2008

## FAX COVER SHEET

TO: USPTO FAX NO: (510) 273-8300  
COMPANY:

FROM: D. Benjamin Borson, Ph.D. REFERENCE NO: ERNZ-01082US3  
DATE: July 22, 2008 TOTAL NUMBER OF PAGES INCLUDING THIS COVER SHEET: 6

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CONTACT:  FAX OPERATOR: (925) 395-2060


NAME:

EXT:

Confirmation will be sent by Mail? {Yes/No} No

MESSAGE:

Dated: July 22, 2008

  
Gina Rocca

The information contained in this facsimile is confidential and may also be attorney-privileged. The information is intended only for the use of the individual or entity to whom it is addressed. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is strictly prohibited. If you have received the facsimile in error, please immediately notify us by a collect telephone call to (925) 395-2060, and return the original message to us via the U.S. Postal Service. Thank you.

RECEIVED  
CENTRAL FAX CENTER

JUL 22 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Peter David Gluckman, et al.

Appl. No.: 10/568,573

Filed: August 10, 2006

Title: Somatogenic Therapy Using a 20kda Placental Variant  
of Growth Hormone

PATENT


Examiner: Scott Long

Confirmation Number: 7135

Art Unit: 1633

Customer Number: 66936

**CERTIFICATE OF TRANSMISSION/MAILING UNDER 37 C.F.R. § 1.8**  
I hereby certify that this correspondence is being facsimile transmitted to the USPTO [total number of pages transmitted 6] or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

  
D. Benjamin Borson, Ph.D., Reg. No. 42,349  
Signature Date: July 22, 2008

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTION OF FILING RECEIPT**

A Filing Receipt in the above-identified patent application was mailed on July 17, 2008.

Please make the following corrections to the Filing Receipt:


Change the Customer Number from 23910 to 66936.

Change the attorney docket number from ERNZ-01016US3 to ERNZ-01082US3.

A copy of the Filing Receipt showing the above changes is provided for your convenience. A copy of the PAIR Bibliographic Data showing the correct docket number and customer number is provided for your convenience. Should you have any questions, please do not hesitate to contact the undersigned attorney.

Respectfully submitted,

Date: July 22, 2008

By: 

D. Benjamin Borson, Ph.D.  
Reg. No. 42,349

Borson Law Group, PC  
1320 Willow Pass Road, Suite 490  
Concord, CA 94520  
Tel: (925) 395-2060/Fax: (925) 395-2061

- 1 -

Attorney Docket No.: ERNZ-01082US3  
ERNZ/01082US3/Request for Correction of Filing Receipt.doc

JUL 22 2008

RECORDED

JUL 21 2008



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE RECD	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/568,573 ✓	08/10/2006 ✓	1633	840	ERNZ-01082US3 1082	21	6

CONFIRMATION NO. 7135

66936

FILING RECEIPT

BORSON LAW GROUP, PC  
1320 WILLOW PASS ROAD  
SUITE 490  
CONCORD, CA 94520-5232

BORSON LAW GROUP, PC

File: ERNZ-01082US3 Atty:

Action Item:

Due Date:

Critical Date:

Docketed By: *[Signature]*

OC000000030947390

Date Mailed: 07/17/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections.

## Applicant(s)

Peter David Gluckman, Auckland, NEW ZEALAND; ✓  
 Robert Stewart Gilmour, Cambridge, UNITED KINGDOM; ✓  
 Mark Hedley Vickers, Auckland, NEW ZEALAND; ✓  
 Bernhard Hermann Heinrich Breier, Auckland, NEW ZEALAND; ✓

## Assignment For Published Patent Application

NEUREN PHARMACEUTICALS LIMITED, Auckland, NEW ZEALAND

Power of Attorney: The patent practitioners associated with Customer Number 23910 66 936

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/27187 08/19/2004  
 which claims benefit of 60/496,970 08/20/2003

## Foreign Applications

If Required, Foreign Filing License Granted: 09/04/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US 10/568,573

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title**

Somatogenic Therapy Using a 20kda Placental Variant of Growth Hormone

**Preliminary Class**

424

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

RECEIVED  
CENTRAL FAX CENTER

JUL 22 2008

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## United States Patent &amp; Trademark Office

Page 1 of 1



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [FAQ](#) | [Glossary](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBIZ Alerts](#) | [News](#) | [Help](#)[Portal Home](#) | [Patents](#) | [Trademarks](#) | [Other](#) | [Sign-Off](#) [Authenticated Session](#)

## Patent eBusiness

- [Electronic Billing](#)
- [Patent Application Information \(PAIR\)](#)
- [Patent Ownership](#)
- [Fees](#)
- [Supplemental Resources & Support](#)

## Patent Information

- [Patent Guidance and General Info](#)
- [Codes, Rules & Manuals](#)
- [Employee & Office Directories](#)
- [Resources & Public Notices](#)

## Patent Searches

- [Patent Official Gazette](#)
- [Search Patents & Applications](#)
- [Search Biological Sequences](#)
- [Goods, Products & Services](#)

## Other

- [Copies](#)
- [Trademarks](#)
- [Policy & Law](#)
- [Results](#)

 Secured Patent Application Information Retrieval XML Download Order Certified Application As Filed    Order Certified File Wrapper    View Order List

10/568,573		Somatogenic Therapy Using a 20kda Placental Variant of Growth Hormone									
Searcher:	Application Number:	Priority Date:	Continued Application Data:	Publication Date:	Document Type:	Classification:	Inventor Name:	Assignee:	Patent Action:	Procedural Status:	Production Review:

## Bibliographic Data

Application Number:	10/568,573	Customer Number:	66936
Filing or 371 (c) Date:	08-10-2006	Status:	Docketed New Case - Ready for Examination
Application Type:	Utility	Status Date:	07-17-2008
Examiner Name:	LONG, SCOTT	Location:	ELECTRONIC
Group Art Unit:	1633	Location Date:	-
Confirmation Number:	7135	Earliest Publication No:	US 2006-0281675 A1
Attorney Docket Number:	ERNZ-01082US3-URBIM	Earliest Publication Date:	12-14-2006
Class / Subclass:	424/093.210	Patent Number:	-
First Named Inventor:	Peter Gluckman , Auckland, (NZ)	Issue Date of Patent:	-
Title of Invention:	Somatogenic Therapy Using a 20kda Placental Variant of Growth Hormone		

## If you need help:

- Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail [EBC@uspto.gov](mailto:EBC@uspto.gov) for specific questions about Patent Application Information Retrieval (PAIR).
- Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).
- If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.

You can suggest USPTO webpages or material you would like featured on this section by E-mail to the [webmaster@uspto.gov](mailto:webmaster@uspto.gov). While we cannot promise to accommodate all requests, your suggestions will be considered and may lead to other improvements on the website.

[Home](#) | [Site Index](#) | [Search](#) | [eBusiness](#) | [Help](#) | [Privacy Policy](#)